%0 Journal Article
%T Targetable domains for the design of peptide-dendrimer inhibitors of SARS-CoV-2.
%A Bellavita R
%A Esposito S
%A Braccia S
%A Madrid L
%A Ortega P
%A D'Auria G
%A Zarrilli F
%A Amato F
%A Galdiero S
%A de la Mata J
%A Falcigno L
%A Falanga A
%J Int J Pharm
%V 661
%N 0
%D 2024 Jun 26
%M 38942185
%F 6.51
%R 10.1016/j.ijpharm.2024.124389
%X We have recently witnessed that considerable progresses have been made in the rapid detection and appropriate treatments of COVID-19, but still this virus remains one of the main targets of world research. Based on the knowledge of the complex mechanism of viral infection we designed peptide-dendrimer inhibitors of SARS-CoV-2with the aim to block cell infection through interfering with the host-pathogen interactions. We used two different strategies: i) the first one aims at hindering the virus anchorage to the human cell; ii) the second -strategy points to interfere with the mechanism of virus-cell membrane fusion. We propose the use of different nanosized carriers, formed by several carbosilane dendritic wedges to deliver two different peptides designed to inhibit host interaction or virus entry. The antiviral activity of the peptide-dendrimers, as well as of free peptides and free dendrimers was evaluated through the use of SARS-CoV-2 pseudotyped lentivirus. The results obtained show that peptides designed to block host-pathogen interaction represent a valuable strategy for viral inhibition.